Market Overview

Perrigo Buys Remaining Stake in Cobrek Pharma for ~$45M

Share:
Related PRGO
Why Perrigo Is Divesting Rights To The Best Multiple Sclerosis Drug
7 Takeaways From Perrigo's Preliminary Q4 Results
Jerome Dodson And The Parnassus Funds: Why Are They So Successful? It's Simple (Seeking Alpha)

Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 million on a cash free and debt free basis.

Posted-In: News M&A

 

Related Articles (PRGO)

View Comments and Join the Discussion!